Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Capricor Therap (NQ: CAPR )

5.710 USD +0.320 (+5.94%)
Official Closing Price Updated: 7:54 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Capricor Therap

< Previous 1 2 3 4 5 6 7 Next >
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
From GlobeNewswire News Releases
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
From GlobeNewswire News Releases
Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?
InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL. 
From PR Newswire
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Trial Assessing Ability of Capricor’s Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 
From GlobeNewswire News Releases
InvestorNewsBreaks – M Vest Unveils List of ‘Latest Companies in the Spotlight’
From InvestorBrandNetwork
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
From GlobeNewswire News Releases
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
From GlobeNewswire News Releases
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET 
From GlobeNewswire News Releases
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
From GlobeNewswire News Releases
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
Capricor Therapeutics to Present at The LD 500 Virtual Conference
From ACCESSWIRE
Thinking about buying stock in Sigma Labs Inc. Common Stock, Viveve Medical Inc, Ovid Therapeutics Inc, Capricor Therapeutics Inc, or Immunovant Inc?
InvestorsObserver issues critical PriceWatch Alerts for SGLB, VIVE, OVID, CAPR, and IMVT. 
From PR Newswire
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
From GlobeNewswire News Releases
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Bullish US Stocks With Highest Surge In The Last One Month: $ALT $KNDI $CAPR
Tags The Market Signal
From The Market Signal
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET 
From GlobeNewswire News Releases
Thinking about buying stock in Riot Blockchain, Onconova Therapeutics, Capricor Therapeutics, Genocea Biosciences, or eMagin Corp?
InvestorsObserver issues critical PriceWatch Alerts for RIOT, ONTX, CAPR, GNCA, and EMAN. 
From PR Newswire
Thinking about buying stock in Caesars Entertainment, Moleculin Biotech, Onconova Therapeutics, Capricor Therapeutics, or Diffusion Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for CZR, MBRX, ONTX, CAPR, and DFFN. 
From PR Newswire
Thinking about buying stock in Lakeland Industries, Capricor Therapeutics, T2 Biosystems, Callon Petroleum, or TOP Ships?
InvestorsObserver issues critical PriceWatch Alerts for LAKE, CAPR, TTOO, CPE, and TOPS. 
From PR Newswire
Capricor to Participate in BIO Digital International Convention
From GlobeNewswire News Releases
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
From GlobeNewswire News Releases
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
Company to Host Conference Call, May 14, 2020, at 4:30 p.m. ET 
From GlobeNewswire News Releases
Thinking about buying stock in Capricor Therapeutics, Waitr, Takeda Pharmaceutical, Sorrento Therapeutics, or Inovio Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for CAPR, WTRH, TAK, SRNE, and INO. 
From PR Newswire
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
From GlobeNewswire News Releases
Thinking about buying stock in Applied DNA Sciences, Agile Therapeutics, Canopy Growth Corp, Fluidigm Corp, or Capricor Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for APDN, AGRX, CGC, FLDM, and CAPR. 
From PR Newswire
Thinking about buying stock in Capricor Therapeutics, NXT-ID Inc, Brinker International, AMC Entertainment, or Biondvax Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for CAPR, NXTD, EAT, AMC, and BVXV. 
From PR Newswire
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients 
From GlobeNewswire News Releases
Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.